// App-Quantinova.ai

588 : Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial

Researchers

Presenter

  • Koji Sasaki

Principal Investigators

  • Elias J. Jabbour

  • Susan M. -Brien

  • Naveen Pemmaraju

  • Yesid Alvarado

  • Jovitta Jacob

  • Rebecca Garris

  • Philip A Thompson

  • Jorge E. Cortes

  • Hagop M. Kantarjian

  • Farhad Ravandi

  • Deborah A Thomas

  • Guillermo Garcia-Manero

  • Naval Daver

  • Gautam Borthakur

  • Nitin Jain

  • Marina Konopleva

  • Nicholas J. Short

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Chao Family Comprehensive Cancer Center, University of California, Orange, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • B-lymphocyte antigen CD20

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Methotrexate

  • Vincristine

  • Cytarabine liposomal

  • Prednisone

  • Rituximab

  • 6-mercaptopurine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved